Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Expand Kidney Disease Treatment Portfolio

The acquisition, valued at $65 per share, marks Vertex's largest deal, aiming to enhance its capabilities in autoimmune and inflammatory diseases.

Vertex Pharmaceuticals has agreed to purchase Alpine Immune Sciences for approximately $4.9 billion, a move that significantly bolsters its kidney disease treatment pipeline.
The deal values Alpine shares at $65, representing a substantial premium over recent trading prices, reflecting the strategic importance of the acquisition.
Alpine's lead molecule, povetacicept, is expected to enter Phase 3 trials later this year for the treatment of IgA nephropathy, a serious autoimmune kidney disorder.
Analysts predict that povetacicept could become a multibillion-dollar product, with potential applications beyond IgA nephropathy.
The acquisition is part of Vertex's broader strategy to diversify its portfolio beyond its traditional focus on cystic fibrosis treatments.